88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) almost never finds itself stuck in the mud and as one project phases into another, investors always seem to have a new set of catalysts on the horizon – and in the coming weeks, Hickory will be the focal point.
hVIVO’s contract win “reflects the fruits” of its business development activities in the Asia Pacific region, said finnCap.
According to the broker, the £6.8mln contract with a leading pharmaceutical company is further evidence of the growing importance of hVIVO’s respiratory syncytial virus (RSV) challenge model in the development of RSV drugs.
Oxford BioDynamics PLC (AIM:OBD) (OBD) rallied over 17% on Monday following a promising update on its Prostate Screening EpiSwitch (PSE) blood test.
Peer-reviewed journal Cancers reported a 94% accuracy rate in a piece detailing the results of a multi-institutional clinical study comprising experts from Oxford BioDynamics, Imperial College London, University of East Anglia and Imperial College NHS Trust.
Research group hVIVO PLC has signed a £6.8mln contract with a second Asia-Pacific pharmaceutical company - building on the business development work it has done in the region.
It has been contracted to conduct a phase IIa human challenge study at its quarantine facilities in Whitechapel, London and will evaluate the efficacy of the antiviral against respiratory syncytial virus (RSV) infection in healthy volunteers.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) has in separate statements revealed that its equity fund raise was oversubscribed and informed investors that it has secured a permit to drill the planned Hickory-1 well in Alaska.
The AIM-quoted explorer, in one statement, said it has raised A$17.5mln, up from the A$15mln targeted, from domestic and international institutional and sophisticated investors, as it successfully completed a bookbuild process. New shares are being issued at 0.95 Australian cents per share (0.55p).
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) has announced a non-exclusive distribution agreement with Mobileye Vision Technologies Ltd to enhance Seeing Machines’ Guardian aftermarket offering.
Under the agreement, Guardian, which targets the commercial fleet sector, will incorporate Mobileeye’s suite of advanced driver assistance systems (ADAS) to alert drivers of potentially dangerous situations.
Empire Metals Ltd (AIM:EEE) has released the results of the dipole-dipole induced polarisation (DD-IP) surveys carried out at the Pitfield copper project in Western Australia.
These DD-IP surveys have identified multiple drilling targets and provided further evidence to support the view that Pitfield has the potential to contain multiple sediment-hosted stratabound copper deposits across a 40 kilometre long alteration footprint.
Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) said it has boosted the gold resource base at its 64%-owned Blanket mine in Zimbabwe.
The total measured and indicated resources estimate at Blanket, inclusive of reserves, has increased by 52% to 1.095mln ounces of gold. Total reserves have increased by 1% to 395,000 ounces of gold.
Bradda Head Lithium Limited (AIM:BHL, OTCQB:BHLIF, TSX-V:BHLI) has reported ‘significant’ high-grade lithium-bearing intercepts at multiple locations from its first diamond core drilling programme at the San Domingo pegmatite district in Arizona.
Best of the results was 32 metres (m) at a grade of 1.6%, with Bradda Head adding that 5,700m of the 7,000m programme had now been completed with a finish this month.
Greatland Gold PLC (AIM:GGP, OTC:GRLGF), the mining and exploration company, said it made two key appointments to its leadership team.
Jeremy Meynert joins as chief development officer and Simon Tyrrell as chief operating officer.
Iofina PLC (AIM:IOF, OTC:IOFNF) said it expects underlying profits for 2022 to be "materially" ahead of market forecasts and not less than US$10.5mln, as prices for iodine have been higher than expected.
Global demand for both iodine and iodine-based derivatives was strong throughout 2022, with prices rising during the first half and remaining high for the remainder of the year
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said its partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former’s discovery and putative treatment for systemic lupus erythematosus (SLE).
The new study design was influenced by guidance from the US Food & Drug Administration (FDA), which suggested exploring higher dose levels than previously used.